MannKind Corporation (MNKD) Could Sink 90%: TourbillionMark Melin
Hedge fund Tourbillion Capital Partners doesn’t like health care stock MannKind Corporation (NASDAQ:MNKD) and is betting it could tumble by as much as 90 percent, CNBC’s Lawrence Delevingne is reporting.
MannKind's Afrezza will fail due to potential customer backlash
Tourbillion thinks MannKind Corporation (NASDAQ:MNKD)’s lead diabetes treatment product, Afrezza, which recently won FDA approval, will fail . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email firstname.lastname@example.org or click Chat.